Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
May 01, 2026 17:05 ET | Source: Eupraxia Pharmaceuticals Inc. VANCOUVER, British…
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026 17:30 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, May…
CORRECTION — Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies…
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026 16:01 ET | Source: Syndax Pharmaceuticals, Inc. NEW YORK,…
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
March 12, 2026 21:03 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British…
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®)…
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142)…
Supernus Pharmaceuticals to Participate in March Investor Conferences
February 23, 2026 18:15 ET | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md.,…
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026 15:10 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British…
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx),…
